Invex has trademarked its repurposed exenatide as Presendin. To date, Invex has focussed its clinical development of Presendin for IIH.

Following a successful Phase II clinical trial in May 2020, the Australian company has progressed Presendin into a single Phase III registration trial in IIH.

The purpose of this trial is to meet the regulatory requirements for market approval of Presendin in Europe, the UK and Australia.